Cardiovascular Effects of Noncardiovascular Drugs

被引：25

作者：

Raj, Satish R. ^{[1
,2
,3
]}

Stein, C. Michael ^{[1
,2
,3
]}

Saavedra, Pablo J. ^{[2
]}

Roden, Dan M. ^{[1
,2
,3
]}

机构：

[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA

来源：

CIRCULATION | 2009年 / 120卷 / 12期

基金：

美国国家卫生研究院;

关键词：

blood pressure; drugs; heart rate; long-QT syndrome; pharmacology; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONGESTIVE-HEART-FAILURE; CORONARY-ARTERY-DISEASE; SUDDEN CARDIAC DEATH; TORSADE-DE-POINTES; MYOCARDIAL-INFARCTION; ANTIPSYCHOTIC-DRUGS; PROTEASE INHIBITORS; ATRIAL-FIBRILLATION; REVERSIBLE CARDIOMYOPATHY;

D O I：

10.1161/CIRCULATIONAHA.107.728576

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Most drugs are not used to treat heart disease. However, such "noncardiovascular" medications can often have cardiovascular effects. In this review, we discuss some cardiovascular manifestations of drugs used for noncardiovascular indications. We discuss these in the text according to the manifestations with which patients present; selected drugs are listed in Table 1 by their indication/drug class. The same medication may appear in different sections, reflecting the varied cardiovascular consequences of a particular drug. We also discuss cardiovascular effects of noncardiovascular drugs that arise indirectly from drug interactions that cause an increase or decrease in the concentration of a cardiovascular drug.

引用

页码：1123 / 1132

页数：10

共 123 条

[1] Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].

Abenhaim, L ;

Moride, Y ;

Brenot, F ;

Rich, S ;

Benichou, J ;

Kurz, X ;

Higenbottam, T ;

Oakley, C ;

Wouters, E ;

Aubier, M ;

Simonneau, G ;

Begaud, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616

[2]

Abeyta BJ, 2001, AM SURGEON, V67, P265

[3] The distribution of body mass index among individuals with and without schizophrenia [J].

Allison, DB ;

Fontaine, KR ;

Heo, M ;

Mentore, JL ;

Cappelleri, JC ;

Chandler, LP ;

Weiden, PJ ;

Cheskin, LJ .

JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (04) :215-220

[4] Consensus development conference on antipsychotic drugs and obesity and diabetes [J].

DIABETES CARE, 2004, 27 (02) :596-601

[5] Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].

Anderson, GL ;

Limacher, M ;

Assaf, AR ;

Bassford, T ;

Beresford, SAA ;

Black, H ;

Bonds, D ;

Brunner, R ;

Brzyski, R ;

Caan, B ;

Chlebowski, R ;

Curb, D ;

Gass, M ;

Hays, J ;

Heiss, G ;

Hendrix, S ;

Howard, BV ;

Hsia, J ;

Hubbell, A ;

Jackson, R ;

Johnson, KC ;

Judd, H ;

Kotchen, JM ;

Kuller, L ;

LaCroix, AZ ;

Lane, D ;

Langer, RD ;

Lasser, N ;

Lewis, CE ;

Manson, J ;

Margolis, K ;

Ockene, J ;

O'Sullivan, MJ ;

Phillips, L ;

Prentice, RL ;

Ritenbaugh, C ;

Robbins, J ;

Rossouw, JE ;

Sarto, G ;

Stefanick, ML ;

Van Horn, L ;

Wactawski-Wende, J ;

Wallace, R ;

Wassertheil-Smoller, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712

[6]

[Anonymous], 2008, COMPLEMENTARY ALTERN

[7] Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes [J].

Antzelevitch, C ;

Sun, ZQ ;

Zhang, ZQ ;

Yan, GX .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (07) :1836-1848

[8] Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease - A Randomized crossover trial [J].

Arruda-Olson, AM ;

Mahoney, DW ;

Nehra, A ;

Leckel, M ;

Pellikka, PA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (06) :719-725

[9] Congestive heart failure is a rare event in patients receiving imatinib therapy [J].

Atallah, Ehab ;

Durand, Jean-Bernard ;

Kantarjian, Hagop ;

Cortes, Jorge .

BLOOD, 2007, 110 (04) :1233-1237

[10] Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy [J].

Awan, GM ;

Calderon, E ;

Dawood, G ;

Alpert, MA .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2000, 320 (01) :69-71

← 1 2 3 4 5 6 7 8 9 10 →